Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposis sarcoma

Drugs

Volumn 71, Issue 18, 2011, Pages 2531-2558

  Duggan, Sean T ^a   Keating, Gillian M ^a   Ferrandina, G ^b   Kesterson, J P ^c   Lorusso, D ^d   Muggia, F ^e  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b CATHOLIC UNIVERSITY   (Italy)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d CATHOLIC UNIVERSITY   (Italy)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adis Drug Evaluations; Breast cancer; Doxorubicin liposomal; Kaposis sarcoma; Multiple myeloma; Ovarian cancer

Indexed keywords

BORTEZOMIB; CAPECITABINE; DOXORUBICIN; NAVELBINE; VINBLASTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW SUPPRESSION; BREAST CANCER; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; HAND FOOT SYNDROME; HUMAN; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; MEDLINE; MULTIPLE MYELOMA; OVARY CANCER; REVIEW; STOMATITIS;

EID: 82955172929     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11207510-000000000-00000     Document Type: Review

References (101)

1. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15 (3): 440-9 (Pubitemid 38444547)
2. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8 Suppl. 2: 17-24 (Pubitemid 37152053)
3. European Medicines Agency. Scientific discussion for Caelyx [online]. Available from URL: http://www.ema. europa.eu/docs/enGB/document-library/EPAR--- Scien tific-Discussion/human/000089/WC500020175.pdf [Accessed 2011 Nov 21]
4. Dando TM, Keating GK. Liposomal doxorubicin: a review of its use in metastatic breast cancer and potential in nonhodgkin lymphoma. Am J Cancer 2005; 4 (3): 193-206 (Pubitemid 41126926)
5. Plosker GL. Pegylated liposomal doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2008; 68 (17): 2535-51
6. Sharpe M, Easthope SE, Keating GM, et al. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002; 62 (14): 2089-126 (Pubitemid 35204042)
7. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 1997; 53 (3): 520-38 (Pubitemid 27117367)
8. European Medicines Agency. Summary of product characteristics: Caelyx (doxorubicin hydrochloride in a pegylated liposomal formulation) 2mg/ml concentrate for infusion [online]. Available from URL: http://www.ema. europa.eu/docs/enGB/document-library/EPAR---Prod uct-Information/human/000089/ WC500020180.pdf [Accessed 2011 Nov 21]
9. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011; 29 (27): 3628-35
10. Alza Corporation. Doxil(doxorubicin HCl liposome injection) for intravenous infusion: US prescribing information [online]. Available from URL: http://www.doxiline.com [Accessed 2011 Nov 21]
11. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004 Jun; 56 (2): 185-229 (Pubitemid 38720829)
12. Vail DM, Amantea MA, Colbern GT, et al. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004; 31 (6 Suppl. 13): 16-35 (Pubitemid 40023240)
13. Voorhees PM, Orlowski RZ. Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma. Clin Lymphoma Myeloma 2007 Apr; 7 Suppl. 4: S156-162 (Pubitemid 46848459)
14. Small GW, Somasundaram S, Moore DT, et al. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 2003; 307 (3): 861-9 (Pubitemid 37494202)
15. Small GW, Shi YY, Edmund NA, et al. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004; 66 (6): 1478-90 (Pubitemid 39564774)
16. Sturzl M, Zietz C, Eisenburg B, et al. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi's sarcoma: clinical, histological and cell biological evaluation. Res Virol 1994; 145 (3-4): 261-9 (Pubitemid 24244527)
17. GabizonA, ShmeedaH, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42 (5): 419-36 (Pubitemid 36649037)
18. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105 (8): 3058-65
19. Zamboni WC. Concept and clinical evaluation of carriermediated anticancer agents. Oncologist 2008 Mar; 13 (3): 248-60 (Pubitemid 351679900)
20. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994 Feb 15; 54 (4): 987-92 (Pubitemid 24085451)
21. Richly H, Grubert M, Scheulen ME, et al. Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors. Int J Clin Pharmacol Ther 2009; 47 (1): 55-7
22. Gabizon A, Isacson R, Rosengarten O, et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2008 Apr; 61 (4): 695-702
23. La-Beck NM, Zamboni BA, Gabzion A, et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol. Epub 2011 May 18
24. Cattel L, Passera R, Katsaros D, et al. Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate administration sequences. Anticancer Res 2006; 26 (1B): 745-50 (Pubitemid 43206043)
25. Jä ger E, Al-Batran S, Saupe S, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): results of the PELICAN study [abstract no. 1022]. J Clin Oncol 2010; 15 Suppl.: (Suppl.)
26. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004 Oct 1; 22 (19): 3893-901 (Pubitemid 41079870)
27. Alba E, Ruiz-Borrego M, Margeli M, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 2010 Jul; 122 (1): 169-76
28. Schering-Plough. The efficacy and safety of pegylated liposomal doxorubicin compared with capecitabine as first line chemotherapy for metastatic breast cancer (study P04445AM2) [ClinicalTrials.gov identifier NCT00266799]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 22]
29. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008 Feb 20; 26 (6): 890-6 (Pubitemid 351398081)
30. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 Jul 15; 19 (14): 3312-22 (Pubitemid 32642183)
31. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007 Jul 1; 25 (19): 2811-8 (Pubitemid 47123191)
32. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010 Jul 1; 28 (19): 3107-14
33. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010 Jul 10; 28 (20): 3323-9
34. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004 Oct; 95 (1): 1-8 (Pubitemid 39286270)
35. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl. 5: v23-30
36. Morgan RJ, Alvaraz RD, Armstrong DK, et al. NCCN Clinical Practice Guidelines in Oncology: ovarian cancer; including fallopian tube cancer and primary peritoneal cancer V.2.2011 [online]. Available from URL: http://www.nccn.org [Accessed 2011 May 5]
37. MarthC,Alexandre J, Hanker LC, et al. Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial [abstract no. 5052]. J Clin Oncol 2011; 29 (Suppl.)
38. Gladieff L, Ferrero A, De Rauglaudre G, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 2011; [Epub]
39. Monk BJ, Herzog TJ, Kaye SB, et al. Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer [abstract no. 5046]. J Clin Oncol 2011; 29 (Suppl.)
40. Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: Outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22 (1): 39-48
41. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007 Sep 1; 25 (25): 3892-901 (Pubitemid 47477266)
42. Blade L, Sonneveld P, San Miguel JF, et al. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 2011 Feb; 11 (1): 44-9
43. Blade J, Sonneveld P, San MJF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008; 8 (6): 352-5
44. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008 Apr 1; 112 (7): 1529-37 (Pubitemid 351441165)
45. Harousseau J-L, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2009; 20 Suppl. 4: ii97-99
46. Anderson KC, Alsina M, Bensinger W, et al. NCCN Clinical Practice Guidelines in Oncology: multiple myeloma V.1.2011 [online]. Available from URL: www.nccn. org [Accessed 2011 Nov 21]
47. Blade J, Rosinol L, Cibeira MT. Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol 2008; 19 Suppl. 7: vii117-120
48. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010 Aug 15; 116 (16): 3969-77
49. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylatedliposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998 Jul; 16 (7): 2445-51 (Pubitemid 28309039)
50. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998 Feb; 16 (2): 683-91 (Pubitemid 28135616)
51. Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004 Aug 20; 18 (12): 1737-40 (Pubitemid 39095795)
52. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989 Sep; 7 (9): 1201-7 (Pubitemid 19220121)
53. Osoba D, Northfelt DW, Budd DW, et al. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest 2001; 19 (6): 573-80 (Pubitemid 32675210)
54. Hengge UR, Esser S, Rudel HP, et al. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer 2001 May; 37 (7): 878-83 (Pubitemid 32323966)
55. European Medicines Agency. Scientific discussion for Caelyx(extension of the indication) [online]. Available from URL: http://www.ema.europa.eu/docs/ enGB/doc ument-library/EPAR---Scientific-Discussion--Variation/human/000089/ WC500020489.pdf [Accessed 2011 Nov 21]
56. Sehouli J, Oskay-Ozcelik G, Kuhne J, et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol 2006 Jun; 17 (6): 957-61 (Pubitemid 43778986)
57. Lorusso D, Naldini A, Testa A, et al. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology 2004; 67 (3-4): 243-9 (Pubitemid 39551708)
58. Al-Batran SE, Meerpohl HG, von Minckwitz G, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70 (2): 141-6 (Pubitemid 43760340)
59. Markman M, Kennedy A,Webster K, et al. Phase 2 trial of liposomal doxorubicin (40mg/m2) in platinum/paclitaxelrefractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000 Sep; 78 (3 Pt 1): 369-72
60. Tanyi JL, Smith JA, Ramos L, et al. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol 2009 Aug; 114 (2): 219-24
61. Kim RJ, Peterson G, Kulp B, et al. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 2005; 97 (2): 374-8 (Pubitemid 40614877)
62. Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001 Aug; 82 (2): 323-8 (Pubitemid 32730611)
63. von Moos R, Thuerlimann BJK, Aapro M, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008; 44 (6): 781-90
64. Kesterson JP, Odunsi K, Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy 2010; 56 (2): 108-11
65. Yildirim Y, Gultekin E, Avci ME, et al. Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer. Int J Gynecol Cancer 2008; 18 (2): 223-7 (Pubitemid 351365224)
66. Lichterfeld M, Qurishi N, Hoffmann C, et al. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection 2005 Jun; 33 (3): 140-7 (Pubitemid 40881105)
67. European Medicines Agency. Summary of product characteristics: yondelis 0.25mg powder for concentrate for solution for infusion [online]. Available from URL: http://www.ema.europa.eu/docs/enGB/document-library/EPAR---Product- Information/human/000773/WC500045832.pdf [Accessed 2011 Nov 22]
68. O'Brien ME. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008 Jan; 19 (1): 1-7 (Pubitemid 350190962)
69. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000 Sep 1; 89 (5): 1037-47
70. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005 Mar; 10 (3): 205-14 (Pubitemid 40463158)
71. Shimada M, Sato S, Otsuki T, et al. Supportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicin [abstract no. e19722]. J Clin Oncol 2011 Jun; 29 Suppl
72. Martschick A, Sehouli J, Patzelt A, et al. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res 2009 Jun; 29 (6): 2307-13
73. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 2010 Jul 1; 28 (19): 3101-3
74. Ferlay J, Shin H, Bray D. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127 (12): 2893-917
75. Cardoso F, Senkus-Konefka E, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl. 5: v15-19
76. Gennari A, Stockler M, Putoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011 Jun; 29 (1): 2144-9
77. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10 Suppl. 3: 20-9 (Pubitemid 43152727)
78. Carlson RW, Allred CD, Anderson BO, et al. NCCN Clinical Practice Guidelines in Oncology: breast cancer V.2.2011 [online]. Available from URL: http://www.nccn. org [Accessed 2011 Nov 21]
79. Sparano JA, Makhson AN, Semiglazov VF, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 2009 Sep 20; 27 (27): 4522-9
80. Wolff AC, Wang M, Li H, et al. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative OncologyGroup trial E3198. Breast Cancer Res Treat 2010 May; 121 (1): 111-20
81. de la Fouchardiere C, Largillier R, Goubely Y, et al. Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE. Ann Oncol 2009; 20 (12): 1959-63
82. Christodoulou C, Kostopoulos I, Kalofonos HP, et al. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II study of the Hellenic Cooperative Oncology Group (He-COG) with biomarker evaluation. Oncology 2009; 76 (4): 275-85
83. Chia S, ClemonsM,Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006 Jun 20; 24 (18): 2773-8 (Pubitemid 46630575)
84. Mlineritsch B, Schabel-Moser R, Andel J, et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009; 32 (1-2): 18-24
85. Vici P, Colucci G, Giotta F, et al. Amulticenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res 2011; 30 (39)
86. Livi L, Meattini I, Scotti V, et al. Pegylated liposomal doxorubicin (Caelyx) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines. J Chemother 2011; 23 (3): 158-62
87. Vorobiof DA, Rapoport BL, Chasen MR, et al. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. Breast 2004; 13 (3): 219-26 (Pubitemid 38937126)
88. Gogas H, Papadimitriou C, Kalofonos HP, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002; 13 (11): 1737-42 (Pubitemid 35439453)
89. Rossi D, Baldelli AM, Casadei V, et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticancer Drugs 2008; 19 (7): 733-7
90. Manente P, Vicario G, Sgarbossa G, et al. Pegylated liposomal doxorubicin for adjuvant treatment of breast cancer in patients refusing therapy with conventional doxorubicin [abstract no. e11097]. J Clin Oncol 2010 Jun 4; 28 Suppl
91. Elsaid AA, Awad NM. Pegylated liposomal doxorubicin and vinorelbine in metastatic breast cancer: Final results of a phase II trial [abstract no. e11050]. J Clin Oncol 2010 Jun 4; 28 Suppl
92. Liu J, Matulonis UA. New advances in ovarian cancer. Oncology (Williston Park) 2010 Jul; 24 (8): 721-8
93. Muggia F, Cannon T, Safra T, et al. Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer [letter]. J Natl Cancer Inst 2011 Jan 19; 103 (2): 160-1
94. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010 Mar; 46 (4): 765-81
95. Ludwig H, Strasser-Weippl K, Schreder M, et al. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann Oncol 2007; 18 Suppl. 9: ix64-70
96. Richardson PG, Laubach J, Mitsiades C, et al. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park) 2010; 24 (3 Suppl. 2): 22-9
97. Buda G, Ricci D, Huang CC, et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. AnnHematol 2010; 89 (11): 1133-40
98. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 Nov 22; 357 (21): 2133-42 (Pubitemid 350146108)
99. Udhrain A, Skubitz KM, Northfelt DW. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int J Nanomed 2007; 2 (3): 345-52 (Pubitemid 350047778)
100. Hengge UR, TossingG,Kouri V, et al. Graduated systemic treatment of AIDS-associated Kaposi sarcoma: in the era of highly active antiretroviral therapy. Am J Cancer 2004; 3 (3): 133-49 (Pubitemid 39221963)
101. Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9 (6): 336-88 (Pubitemid 352015641)